FindTrial
Sign In

CMVpp65-A*0201 peptide vaccine

BIOLOGICAL2 trials

Sponsors

City of Hope Medical Center

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Hodgkin LymphomaAdult Lymphoblastic LymphomaAdult Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Phase 1

Cytomegalovirus Vaccine in Healthy Participants
CompletedNCT00712634
City of Hope Medical CenterPrecancerous/Nonmalignant Condition
Start: 1997-11-30End: 2009-04-30Target: 46Updated: 2009-12-21

Phase 2

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
CompletedNCT02396134
City of Hope Medical CenterAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission +11
Start: 2015-05-21End: 2024-09-19Updated: 2025-03-03

Related Papers

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant
Blood2021-11-053 citations
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.
2015-12-2462 citations